Drugs / TP-03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04475432 | Sep 2020 → May 2021 | blepharitis | Tarsus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT04784091 | Apr 2021 → May 2022 | blepharitis | Tarsus Pharmaceuticals, Inc. | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-23 | Tarsus Pharmaceuticals, Inc. | TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus tarsusrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784091 ↗ |
| Route | Topical | “TP-03, lotilaner ophthalmic solution, 0.25%, administered topically twice a day” NCT04475432 ↗ |